Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14. - Test2 - elhamkhani - TriplyDB

Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14.

Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14.

http://www.wikidata.org/entity/Q40683812

about

Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection Antimicrobial susceptibility of Clostridium difficile isolated in Thailand Surveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait.Emergence and spread of moxifloxacin-resistant Clostridium difficile ribotype 231 in Sweden between 2006 and 2015.Genome Analysis of Clostridium difficile PCR Ribotype 014 Lineage in Australian Pigs and Humans Reveals a Diverse Genetic Repertoire and Signatures of Long-Range Interspecies Transmission.Human Clostridium difficile infection caused by a livestock-associated PCR ribotype 237 strain in Western Australia.Proton pump inhibitors and risk of Clostridium difficile infection: a multi-country study using sequence symmetry analysis.Recreational sandboxes for children and dogs can be a source of epidemic ribotypes of Clostridium difficile.A Phenotypically Silent vanB2 Operon Carried on a Tn1549-Like Element in Clostridium difficile.Clostridium difficile clade 5 in Australia: antimicrobial susceptibility profiling of PCR ribotypes of human and animal origin.Infection with Toxin A-Negative, Toxin B-Negative, Binary Toxin-Positive Clostridium difficile in a Young Patient with Ulcerative Colitis

P2860

Q26767079-7C2C481F-21CE-4059-8584-B11783795D51 Q33781513-99633B6B-777E-4F2B-B31E-C959EB796306 Q36106735-0FA41112-0FBD-4BDF-A2B1-9493EA36491D Q37333929-083B48CC-988B-4BA2-97C8-FBE851FA2699 Q37578190-2B6FC5C7-7DCB-46D1-8B0D-5EC2D1653426 Q37671582-5C8887DE-457B-4193-A2C3-BB6FA1FD8796 Q39373841-65C522CD-FE8B-4A7D-8BB2-2A385B553D5C Q40144431-BFDA1533-53F7-4D57-9D63-CE5E6A48202F Q40571433-B6196A30-D34E-4872-871B-B917F74C2A75 Q40693155-B58F071E-26B9-4304-A042-BF684CC08517 Q41007833-AA101566-0EA3-485E-8541-490C57FDA974

P2860

Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14.

http://www.wikidata.org/entity/Q40683812

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Surveillance for antimicrobial ...... lostridium difficile, 2013-14.

@en

type

label

Surveillance for antimicrobial ...... lostridium difficile, 2013-14.

@en

prefLabel

Surveillance for antimicrobial ...... lostridium difficile, 2013-14.

@en

P1433

Q40683812-7B3B2444-DFF3-4FFE-AE76-31CCC6375D02

P1476

Q40683812-8C973D47-7FA4-4F71-A64A-9166E7E132EF

P2093

Q40683812-02CA971F-D25D-42C7-A41B-F5F5571B8146

Q40683812-06284EDC-4362-4B72-8675-1F7A69066145

Q40683812-107196AE-B9BF-4DBA-995D-9905303E1683

Q40683812-4E19D1D7-5AF8-4AA8-B8E5-2F26A8AB83DC

Q40683812-60BE46C9-B362-4B4E-9722-5D3AC1A15374

Q40683812-6FF938C8-D513-4334-B181-9B9D78C9546E

Q40683812-98B801E2-4180-49A6-943A-069740CA56F0

Q40683812-A6574E23-7847-44F3-968E-20020D10A30A

Q40683812-A7B93732-EB54-4560-B069-E83253FF0642

Q40683812-F2F1484F-0E39-4093-92B4-9A903A550B11

P2860

Q40683812-0C26F60C-C313-45B8-A386-435DC0AD6253

Q40683812-18AEA30D-F2D7-4EEE-852F-AF3426A31C45

Q40683812-20E14A38-3F3D-4B56-A4BA-AF738122D8C2

Q40683812-22314295-B08D-4466-8B94-2C5FB92BD454

Q40683812-26B94145-AC48-4A3E-8D78-21F0E7E4FEC7

Q40683812-348440B8-CD7C-4BBA-9D33-B16FC11CE344

Q40683812-34D8B5C6-516C-4CBF-A9A7-790DCF41AAC3

Q40683812-3735DB75-9593-40EB-8389-DB9B7B9CF31D

Q40683812-391D5FA5-D4E8-4991-A2AC-5AC4F5739362

Q40683812-492F5007-26CC-424B-8E26-38724461DB9B

P304

Q40683812-6F25FF32-5209-4A23-AC4E-000DD4C86904

P31

Q40683812-D331B820-A38B-4F46-9555-337E9D4A2356

P356

Q40683812-28C2F9B4-5D41-48A7-A24A-8CAAD1EE1A14

P407

Q40683812-36C81DEC-4D94-4F6A-852C-968217353566

P433

Q40683812-18F47245-FAC4-47B2-96DF-4F5471BC53EC

P478

Q40683812-FB42F2B3-838A-4161-BC26-0C9905F90824

P50

Q40683812-659D7DD1-1742-4552-B935-B35BAA307E44

Q40683812-A71CB90B-FD76-45A9-B669-CF6A48D07D10

Q40683812-B643D432-013E-40F1-960F-CE130D3A9E05

Q40683812-E918A3BA-84A9-45C3-A9D8-A1CFF2328D9D

P577

Q40683812-3FC3EF75-0814-4552-94A2-3972AC26CABE

P5875

Q40683812-3F911CF6-2E3B-4D29-A990-720A152F5961

P698

Q40683812-CF6199D0-A473-4DB5-8913-15F0174F1649

P921

Q40683812-ADE90D83-0A05-4CDC-AB77-1F9E877A433E

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Surveillance for antimicrobial ...... lostridium difficile, 2013-14.

@en

P2093

Casey V Moore

http://www.w3.org/2001/XMLSchema#string

Despina Kotsanas

http://www.w3.org/2001/XMLSchema#string

Gerhard F Weldhagen

http://www.w3.org/2001/XMLSchema#string

Jennifer Robson

http://www.w3.org/2001/XMLSchema#string

Louise Prendergast

http://www.w3.org/2001/XMLSchema#string

Lynette Waring

http://www.w3.org/2001/XMLSchema#string

Michael C Wehrhahn

http://www.w3.org/2001/XMLSchema#string

Peter G Huntington

http://www.w3.org/2001/XMLSchema#string

Richard M Wilson

http://www.w3.org/2001/XMLSchema#string

Steven Giglio

http://www.w3.org/2001/XMLSchema#string

P2860

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients

Clostridium difficile infection in the community: a zoonotic disease?

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI).

Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013

Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile.

Clostridium difficile--more difficult than ever.

Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong.

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

P304

2992-2999

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKV220

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Charlotte A Huber

Daniel R Knight

David L Paterson

P577

2015-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280545282

http://www.w3.org/2001/XMLSchema#string

P698

26221017

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile